• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Riluzole/Tiglutik

Background

Riluzole is a drug used to treat people with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). Riluzole is not a cure for ALS/MND, but it may extend survival or time until tracheostomy. It is available in three dosage forms: tablet, oral suspension, and thin film.

The tablet form, Rilutek, was approved by the Food and Drug Administration (FDA) in USA in 1995 and by the European Medicine Agency (EMA) in Europe in 1996.

The oral suspension form, Tiglutik or Teglutik, which is designed for people living with ALS/MND who have difficulty swallowing tablets, is currently approved in many countries including USA, Canada, Europe, Israel, Australia, Brazil, Japan, and China.

The thin film form is available in the US (with the commercial name of Exservan), and in the UK and the EU (with the commercial name of Emylif).

Proposed Mechanism of Action

Neurons have a finely regulated system that allows chemical signals (neurotransmitters) to be translated into electrical signals, which travel much faster and allow efficient communications among neurons. This mechanism is essential for the correct functioning of the human brain, and it is particularly important for motor neurons, which are among the largest neurons in the central nervous system.

ALS/MND is characterized by a progressive and selective death of motor neurons, the causes of which are mostly unknown. One of the mechanisms thought to be involved in this process is excitotoxicity, which occurs when neurons are exposed to excessive levels of a neurotransmitter called glutamate, causing a dysregulated neuronal activation. This may lead to neuronal damage and eventual death.

Riluzole was the first compound ever approved for the treatment of ALS/MND. Riluzole’s mechanism of action is not fully understood; however, it is thought to interfere with the excessive glutamate release that leads to excitotoxicity in ALS/MND.

Of note, other clinical trials in people living with ALS/MND with compounds that have a similar mechanism of action have failed. Therefore, riluzole’s action has been hypothesized to expand to other aspects of neurotransmission or even other molecular mechanisms linked to ALS/MND. These hypotheses are currently under investigation.

Clinical Trials

Riluzole was approved based on two international clinical trials that included a total of 1,114 people living with ALS/MND (PALS).

In the first study, 155 PALS were treated with 100 mg of riluzole or placebo daily for 12 months. By the end of the study, the treatment extended survival or time until tracheostomy (where a breathing tube is inserted directly into the throat) by roughly three months compared to placebo.

In the second study, 959 PALS were treated with three different concentrations of riluzole (50 mg, 100 mg, 200 mg) or placebo daily for 18 months. Both the 100 mg and 200 mg treatments extended survival or showed significant delay in the need for tracheostomy when compared to placebo. However, the 200 mg dose resulted in more side effects.

Dose and Administration

Riluzole comes in three forms and has several brand names:

  • Tablet form: Rilutek contain 50 mg of the active compound (riluzole). The recommended dose is 50 mg twice daily (every 12 hours) taken orally.
  • Oral suspension form: Tiglutik or Teglutik is recommended for patients who have difficulty in swallowing or receive nutrition via feeding tube. The dosage recommendation is the same as Rilutek. The FDA approved Tiglutik in 2018, whereas Teglutik has been available in the UK since 2015.
  • Thin film form: Exservan/Emylif dissolves on the tongue. It is applied one to two hours prior to a meal.

Riluzole is recommended for all patients diagnosed with ALS/MND. However, due to lack of studies, it is unclear whether it is equally effective after five years from symptom onset.

Reported Side Effects

Riluzole is safe and generally well tolerated at a dose of 100 mg daily for up to seven years. The most common side effects are numbness around the mouth, nausea, dizziness, diarrhea, lack of energy, high blood pressure, decreased lung function, and abdominal pain. Rare cases have reported liver injury.

In 2020, a study showed that out 15 peer-reviewed studies in PALS treated with riluzole in real-world settings, eight found that survival was a median of 6 to 19 months longer on riluzole than on placebo. Riluzole’s effects and safety continue to be investigated in people living with ALS/MND.

Riluzole should be administered and monitored under the care of a physician.

Disclaimer: Consult with your doctor to determine if riluzole is an option for you. Always disclose your medical history, including any drugs, natural supplements, or herbal medicines you are currently using. Your doctor will determine the right plan for your needs.

Sources

  • https://www.ajmc.com/view/diseasemodifying-treatment-of-amyotrophic-lateral-sclerosis
  • https://www.sciencedirect.com/science/article/abs/pii/S0028390820300526?via%3Dihub
  • https://go.drugbank.com/drugs/DB00740
  • https://pubmed.ncbi.nlm.nih.gov/16806844/ 
  • https://www.nejm.org/doi/full/10.1056/NEJM199403033300901#t=article 
  • https://www.sciencedirect.com/science/article/abs/pii/S0140673696916803 
  • https://alsnewstoday.com/rilutek-riluzole-for-als/#Clinical_trials

The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Approved Drugs

  • Nuedexta
  • Radicava/Edaravone
  • Riluzole/Tiglutik
  • Rozebalamin/Methylcobalamin
  • Tofersen/Qalsody

  • Dr Shelly Hoover

    Dr Shelly Hoover

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Frank "Papa" Taylor

    Frank “Papa” Taylor

  • Shay Rishoni

    Shay Rishoni

  • Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

    Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

  • Jack Buzby, USA

    Jack Buzby, USA

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Brian Lovell, Diagnosed 2011 . MND Australia

    Brian Lovell, Diagnosed 2011 . MND Australia

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • England-Lee-Millard, UK

    England-Lee-Millard, UK

  • Irene McCaughey, Diagnosed 2011,  MND Australia

    Irene McCaughey, Diagnosed 2011, MND Australia

  • Steve Gallagher, ALS Society of Canada

    Steve Gallagher, ALS Society of Canada
    Picture1

  • H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

    H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

  • Jo Knowlton and her dog, Scotland

    Jo Knowlton and her dog, Scotland

  • Joy Blakeley, Diagnosed 2017 , MND Australia

    Joy Blakeley, Diagnosed 2017 , MND Australia

  • Fabio Carvalho

    Fabio Carvalho

  • Kirsty Gerlach, MND New Zealand, Diagnosed 2017

    Kirsty Gerlach, MND New Zealand, Diagnosed 2017

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Shay Rishoni, Diagnosed 2011 - Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 – Prize4Life, Israel

  • Karl Hughes, Diagnosed 2010 , IMNDA,  Ireland

    Karl Hughes, Diagnosed 2010 , IMNDA, Ireland

  • Zelina Brito, Diagnosed 2018, Brazil

    Zelina Brito, Diagnosed 2018, Brazil

  • Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

    David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

  • Cath Muir

    Cath Muir
    Cath

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

    Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

  • Paul Launer, USA

    Paul Launer, USA

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Hanne Stenmose, Muskelsvindfonden, Denmark

    Hanne Stenmose, Muskelsvindfonden, Denmark

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Claudette Sturk, ALS Society of Canada

    Claudette Sturk, ALS Society of Canada
    Picture2

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

    Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

  • Willi Klein

    Willi Klein

  • Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

    Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

  • Richard Clark, MND New Zealand,  Diagnosed 2011

    Richard Clark, MND New Zealand, Diagnosed 2011

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Leon Ryba, Asociación ELA Argentina

    Leon Ryba, Asociación ELA Argentina

  • Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

    Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

  • João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

    João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

  • Gudjon Sigurdsson, Diagnosed 2004 , MND Association of Iceland

    Gudjon Sigurdsson, Diagnosed 2004 , MND Association of Iceland

  • Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

    Sanjay Kumar Srivastava, Asha Ek Hope Foundation for ALS/MND, Diagnosed 2018, India

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Lombana, Spain

    Lombana, Spain

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Liam Dwyer, England

    Liam Dwyer, England

  • Ali Var, Turkey

    Ali Var, Turkey

  • Mary Thomas, Diagnosed 2013 , MND Australia

    Mary Thomas, Diagnosed 2013 , MND Australia

  • Art Eggert, USA

    Art Eggert, USA

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login